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Serious hypersensitive symptoms associated with chemotherapy for 
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The serious hypersensitive symptoms associated with chemotherapy 
for lung cancer can pose a fatal and signiﬁcant problem although their 
frequency is low.
We present two cases which we encountered recently, together with 
some bibliographical comments.
Case 1: 71-year-old male with adenocarcinoma. A ﬁrst course of 
combination chemotherapy consisting of carboplatin and docetaxel 
was administered. Adverse reactions were limited to mild myelosup-
pression and alopecia. Because the antitumor effect of this combination 
chemotherapy was judged to be no change (NC), radiotherapy was 
concomitantly used. When radiotherapy was applied in a dose of 12 Gy, 
a second course of combination chemotherapy was administered. Pre-
treatment with steroids was followed by administration of docetaxel. A 
few minutes later, the patient felt pain in his chest. The drug treatment 
was immediately terminated but he developed cardiopulmonary arrest. 
Cardiopulmonary resuscitation and artiﬁcial respiration were performed 
and treatment was continued. The patient, however, died of resuscita-
tion encephalopathy on day 45. The frequency of hypersensitive symp-
toms resulting from administration of docetaxel was studied in 1,029 
cases. Those who developed shock symptoms and those who developed 
anaphylactoid reaction accounted for 0.1% and 0.3% respectively. 
There are two reported fatalities. 
Case 2: 79-year-old male with small cell carcinoma. A ﬁrst course of 
combination chemotherapy consisting of carboplatin and irinotecan was 
administered. This patient also underwent pretreatment with steroids. 
Immediately before completion of the administration of irinotecan, the 
patient complained of breathing difﬁculties although no speciﬁc aller-
gic symptoms were recognized. Chemotherapy was continued while re-
ducing the infusion rate. Administration of carboplatin was continued. 
Approximately one hour after completion of administration, the patient 
developed facial edema and stridor. Because these symptoms suggested 
anaphylaxis, steroids and epinephrine were administered. Respiratory 
conditions did not improve and the patient was transferred to ICU for 
artiﬁcial respiration. At the time of intubation, marked epiglottal hyper-
emia/edema was recognized. Despite stabilization of respiratory condi-
tions, the patient developed gastrointestinal bleeding and sepsis. These 
symptoms, however, subsided after treatment. The patient suffered 
myocardial infarction on day 24 and died on day 25. The frequency of 
hypersensitive symptoms resulting from administration of irinotecan 
was studied in 16,109 cases. Those who developed anaphylactoid reac-
tion and those who developed shock symptoms accounted for 0.01% 
(2 cases) and 0.006% (1 case) respectively. No fatalities have been 
reported so far.The frequency of hypersensitive symptoms resulting 
from administration of carboplatin was studied in 6,218 cases in Japan. 
Those who developed an anaphylactoid reaction accounted for 0.03% 
(2 cases). No fatalities have been reported so far.
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Background: Chemotherapeutic agents should have a demonstrable 
anti tumor activity, which should be reproducible at all centers across 
the globe. In the late 1970s, the International Union against Cancer 
and the World Health Organization introduced speciﬁc criteria for the 
codiﬁcation of tumor response evaluation. This is modiﬁed in 1994 and 
validated by many and presently we are following the one designed by 
“Response Evaluation Criteria in Solid Tumors -RECIST Group”. 
We thought of comparing the RECIST response to WHO in patients of 
lung cancer.
Aim: Comparison of WHO and RECIST criteria for assessment of 
response in patients with lung cancer
Methods: A total of 96 previously untreated patients with locally 
advanced or metastatic NSCLC during 2004 to 2006 with an ECOG 
performance status (PS) scale of ≤ 2 were included. Patients received 
either a combination of Gemcitabine and Cisplatin; Gemcitabine and 
Carboplatin or single cisplatin with etoposide. Gemcitabine was given 
at a dosage of 1250mg/m2 on days 1and 8 of a 3 weekly cycle, while 
Cisplatin was given at 75-100mg/m2 and Carboplatin at an AUC of 6 
once every three weeks. Etoposide was given as 100mg/m2 infusion per 
day over 3 days. Response was assessed as per the RECIST criteria as 
well as WHO criteria. Assessment was done at end of every 2nd cycle 
and conﬁrmed after 4 weeks of initial response. The test is repeated if 
clinically indicated.
Results: the responses were shown in the table below:
Gemcitabine + 
Cisplatin
Gemcitabine + 
Carboplatin
Cisplatin with 
etoposide
Total
No. of Patients 32 24 40 96
At the end of therapy (RECIST)
Partial Response 50% 50% 20% 35%
Stable Disease 25% 16% 25% 20%
Progressive disease 25% 34% 55% 45%
At the end of therapy (WHO)
Partial Response 38% 24% 14% 36%
Stable Disease 38% 33% 25% 29%
Progressive disease 25% 43% 61% 35%
Pearson’s correlation coeﬃcient showed a signiﬁcant positive correlation r=0.8 (95% CI= 0.6-0.9) 
p=0.02. 
Conclusion: However there are some observed differences like more 
PR as measured by RECIST in contrast to the WHO. The higher rates 
of RCIST are probably due to the one-dimensional measurement, 
which often ignores the increment in the other dimension, which WHO 
will consider. 
